This was the first Chinese lifetime economic evaluation of the first-line IB strategy versus the BE plus RI strategy for the treatment of 65 or older patients with untreated CLL without the del (17p)/TP53 mutation from the perspective of Chinese health care system. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.